Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1498
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4681    
    Printed160    
    Emailed1    
    PDF Downloaded414    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 

 HEMATOLOGICAL MALIGNANCIES - REVIEW ARTICLE
Year : 2011  |  Volume : 48  |  Issue : 4  |  Page : 438-445

Nilotinib as first-line therapy for chronic myeloid leukemia


Department of Medical Oncology, Cancer Institute, Medanta Hospital, Medicity, Sector 38, Gurgaon, NCR, Delhi, India

Correspondence Address:
A Vaid
Department of Medical Oncology, Cancer Institute, Medanta Hospital, Medicity, Sector 38, Gurgaon, NCR, Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-509X.92274

Rights and Permissions

Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow